All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024
On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
PostNews: Press Release
Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing
PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
PostNews: Press Release
New Distributor Partner Manager at Altium set to enhance global sales for PHI
PHI is conveying the news that its global distributor, Altium ., has appointed a PHI-dedicated distributor partner manager. This strategic step is set to significantly enhance the reach and sales performance of PHI’s HoloMonitor technology on a global scale.
PostNews: Press Release
Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 14 March 2024
Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an extraordinary general meeting on 14 March 2024 at 10.00 am at the Company’s premises, Skiffervägen 48 in Lund.
PostNews
BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
PostNews: Press Release
PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024
PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
Biostock interview with CEO Peter Egelberg
New CEO commentary — “Redefining aging with HoloMonitor”
In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.
New CEO commentary: “The scientific role of commercialization”
On PHI’s website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”, see CEO commentary The scientific role of commercialization, published February 18, 2018.